Biomea Fusion (BMEA) to Release Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) will likely be releasing its earnings data before the market opens on Monday, March 24th. Analysts expect Biomea Fusion to post earnings of ($1.00) per share for the quarter.

Biomea Fusion Price Performance

Shares of NASDAQ BMEA opened at $2.87 on Friday. Biomea Fusion has a 12 month low of $2.35 and a 12 month high of $16.29. The company has a 50-day simple moving average of $3.47 and a 200-day simple moving average of $6.17. The company has a market cap of $104.01 million, a PE ratio of -0.72 and a beta of -0.26.

Analyst Ratings Changes

A number of equities analysts have recently commented on BMEA shares. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Biomea Fusion in a report on Tuesday, January 14th. D. Boral Capital restated a “buy” rating and issued a $16.00 price target on shares of Biomea Fusion in a report on Wednesday. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $29.18.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.